Stay updated on Pharmacokinetics Safety BI 695502 Healthy Subjects Clinical Trial

Sign up to get notified when there's something new on the Pharmacokinetics Safety BI 695502 Healthy Subjects Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pharmacokinetics Safety BI 695502 Healthy Subjects Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the pharmacokinetics and safety study of BI 695502 in healthy subjects, specifically focusing on establishing biosimilarity compared to bevacizumab.
    Difference
    0.2%
    Check dated 2024-06-06T14:31:39.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying that researchers are looking for healthy males aged 21 to 50 with specific health and physical conditions. Previously, this section had no information provided.
    Difference
    21%
    Check dated 2024-05-22T21:19:30.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    2%
    Check dated 2024-04-30T22:13:32.000Z thumbnail image

Stay in the know with updates to Pharmacokinetics Safety BI 695502 Healthy Subjects Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pharmacokinetics Safety BI 695502 Healthy Subjects Clinical Trial page.